ATS 2024 Final Program

Click on the session title to view the speakers

SUNDAY • MAY 19

41

P397 Impact of Asthma on the Severity of COVID-19 Infection: 2020 National Inpatient Sample Analysis P398 Systemic Application of Pam3-FSL-1 Alters Antibody Isotype Composition and Reduces Experimental Allergic Airway Inflammation in Mice P399 Post-translational Modification of Human IL-33 Mediated by Protein Kinase C Family Impacts Cytokine Inflammatory Activity P400 Transforming Asthma Diagnosis: Point of Care (POC) Breath Test With Deep Neural Networks (DNNs) and Nanosensors P401 Advancing Asthma Management: Recurrent Neural Networks (RNNS) and Nanosensors for Precision Forecasting of Indoor Air Pollution P402 Oral Corticosteroid-sparing Effects of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis (EGPA): Results Up to 7.4 Years From the Long-term Access Programme P403 Cysteinyl Leukotrienes Are Required for Rhinovirus-induced Mucous Metaplasia in Immature Mice P404 8-iso-prostaglandin F2alpha as a Biomarker of Type 2-Low Airway Inflammation and Remodeling in Adult Asthma P405 Effect of Dupilumab Treatment on Mucus Plugging and Mucus Volume in Type 2 Asthma: The Phase 4 VESTIGE Trial P406 Phase 1 Safety and Efficacy of AZD8630/AMG 104 Inhaled Anti-TSLP in Healthy Volunteers and Patients With Asthma on Medium-High Dose Inhaled Corticosteroid (ICS) and Long-Acting Beta-agonist (LABA) With Elevated Baseline Fractional Exhaled Nitric Oxide (FeNO) P407 Sympathetic Nervous Regulation of Lung Adaptive Immunity P408 Pathogenic Potential of CD8+ TEMRAsIn Severe Asthma

BEHAVIORAL • CLINICAL THEMATIC POSTER SESSION

A35 ASTHMA AND COPD: EPIDEMIOLOGY, TREATMENT, OUTCOMES, AND SOCIAL DETERMINANTS 9:15 a.m. - 4:15 p.m. San Diego Convention Center Area B (Hall A-B2, Ground Level) Viewing: Posters will be on display for entire session Discussion: 11:30-12:30 Discussion with facilitators, authors, and attendees 12:30-1:15 Authors will be by their posters for individual discussion with attendees P111 Developing a Risk Calculator Tool to Reduce Respiratory Viral Transmission in Classrooms P112 Measuring Meaningful Change in Patients With Asthma Using the Asthma Daytime and Asthma Nighttime Symptom Diaries P113 Real-world Adherence to Biologics and Association With Health Outcomes in Patients With Asthma: A Systematic Literature Review P114 Experience With Biologic Therapy for Asthma in an Urban Hospital P115 Patient Characteristics and Treatment Patterns With Tezepelumab in the United States: An Early Claims Data Study P116 De-escalation of Asthma Therapy After Initiation of Biologics for Severe Asthma in an Ambulatory Setting P117 Assessing Inhaler Technique With Innovative Sensor Technology P118 Performance of a Portable Spacer Compared to the Metered Dose Inhaler Alone and a Commonly Recommended Spacer P119 Evaluation of Child-mask Spacers Using an Oro-nasopharynx Model for the Aerosol Delivery of a Widely Prescribed Corticosteroid P120 Patients’ Views of Reliever Budesonide-formoterol Inhalers for Mild Asthma in the United States P121 Sales Trend Analysis of SABA, LABA/ICS and ICS Isolated in Brazil: A 2019-2022 Series P122 Timely Outcomes

ATS 2024 Conference Program • San Diego, CA